Science
Aakash Desai: Lung Cancer ADC and Bispecific Pipelines Target the Same Few Antigens
Aakash Desai/LinkedIn

Aakash Desai: Lung Cancer ADC and Bispecific Pipelines Target the Same Few Antigens

Aakash Desai, Thoracic and Phase 1 Oncologist at the O’Neal Comprehensive Cancer Center at UAB, shared on X:

“Agree, lung cancer ADC/BsAb pipelines look the same.

We mapped 47 active trials:

  • BsAbs ~70% / ADCs ~30%
  • Top BsAb: EGFR×c-MET (~28%)
  • Top ADC: TROP2 (~33%), HER2 (~20%)

Same few antigens. More me-too than novel.

Title: Biomarker Landscape of Antibody Drug Conjugates (ADCs) and Bispecific Antibodies in Clinical Trials for Lung Cancer

Authors: Madhan Srinivasan Kumar, Sameer Deshmukh, Charmi Bhanushali, Yanis Boumber, Johnathan Riess, Abdul Rafeh Naqash, Vivek Subbiah, Aakash Desai.

Read The Full Article.”

Aakash Desai: Lung Cancer ADC and Bispecific Pipelines Target the Same Few Antigens

Other articles about Lung Cancer on OncoDaily.

 

Aakash Desai Abdul Rafeh Naqash ADCs Antibody drug conjugates Bispecific antibodies bsAbs c-MET cancer Charmi Bhanushali clinical trials EGFR HER2 Johnathan Riess Lung cancer Madhan Srinivasan Kumar OncoDaily Oncology Sameer Deshmukh TROP2 Vivek Subbiah Yanis Boumber